OXUR Stock Overview
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||€0.32|
|52 Week High||€2.59|
|52 Week Low||€0.28|
|1 Month Change||-18.97%|
|3 Month Change||-47.51%|
|1 Year Change||-84.88%|
|3 Year Change||-88.87%|
|5 Year Change||-89.81%|
|Change since IPO||-93.19%|
Recent News & Updates
|OXUR||BE Biotechs||BE Market|
Return vs Industry: OXUR underperformed the Belgian Biotechs industry which returned -14.1% over the past year.
Return vs Market: OXUR underperformed the Belgian Market which returned -6.3% over the past year.
|OXUR Average Weekly Movement||17.9%|
|Biotechs Industry Average Movement||8.1%|
|Market Average Movement||4.7%|
|10% most volatile stocks in BE Market||8.1%|
|10% least volatile stocks in BE Market||2.6%|
Stable Share Price: OXUR is more volatile than 90% of Belgian stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: OXUR's weekly volatility has increased from 12% to 18% over the past year.
About the Company
Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME.
Oxurion Fundamentals Summary
|OXUR fundamental statistics|
Is OXUR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OXUR income statement (TTM)|
|Cost of Revenue||€612.00k|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Sep 07, 2022
|Earnings per share (EPS)||-0.57|
|Net Profit Margin||-2,584.93%|
How did OXUR perform over the long term?See historical performance and comparison
Is OXUR undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for OXUR?
Other financial metrics that can be useful for relative valuation.
|What is OXUR's n/a Ratio?|
Price to Sales Ratio vs Peers
How does OXUR's PS Ratio compare to its peers?
|OXUR PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
BOTHE Bone Therapeutics
MTPH Midatech Pharma
Price-To-Sales vs Peers: OXUR is good value based on its Price-To-Sales Ratio (14.4x) compared to the peer average (21.9x).
Price to Earnings Ratio vs Industry
How does OXUR's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Sales vs Industry: OXUR is good value based on its Price-To-Sales Ratio (14.4x) compared to the European Biotechs industry average (16.1x)
Price to Sales Ratio vs Fair Ratio
What is OXUR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||14.4x|
|Fair PS Ratio||3.5x|
Price-To-Sales vs Fair Ratio: OXUR is expensive based on its Price-To-Sales Ratio (14.4x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).
Share Price vs Fair Value
What is the Fair Price of OXUR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate OXUR's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate OXUR's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
- Take a look at our analysis of OXUR's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Oxurion regulatory filings.
How is Oxurion forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OXUR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OXUR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OXUR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OXUR's revenue is expected to decline over the next 3 years (-31.3% per year).
High Growth Revenue: OXUR's revenue is forecast to decline over the next 3 years (-31.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OXUR's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Oxurion performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OXUR is currently unprofitable.
Growing Profit Margin: OXUR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OXUR is unprofitable, and losses have increased over the past 5 years at a rate of 2.4% per year.
Accelerating Growth: Unable to compare OXUR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OXUR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.2%).
Return on Equity
High ROE: OXUR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
How is Oxurion's financial position?
Financial Health Score0/6
Financial Health Score 0/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: OXUR has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: OXUR has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: OXUR has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: OXUR's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OXUR has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: OXUR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 10.3% each year
Discover healthy companies
What is Oxurion current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OXUR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OXUR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OXUR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OXUR's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as OXUR has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tom Graney (57 yo)
Mr. Thomas Graney, also known as Tom, C.F.A., is a Non-Executive Director at Mogrify Limited since November 2021. He serves as Director at Oxurion NV since August 2021. He serves as Chief Financial Officer...
CEO Compensation Analysis
Compensation vs Market: Tom's total compensation ($USD481.03K) is about average for companies of similar size in the Belgian market ($USD488.26K).
Compensation vs Earnings: Insufficient data to compare Tom's compensation with company performance.
Experienced Management: OXUR's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: OXUR's board of directors are considered experienced (7.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.9%.
Oxurion NV's employee growth, exchange listings and data sources
- Name: Oxurion NV
- Ticker: OXUR
- Exchange: ENXTBR
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €16.150m
- Shares outstanding: 51.27m
- Website: https://www.oxurion.com
Number of Employees
- Oxurion NV
- Gaston Geenslaan 1
- Flemish Brabant
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/17 00:00|
|End of Day Share Price||2022/08/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.